Effect of Intensive Atorvastatin Therapy on Periprocedural PDCD4 Expression in CD4+ T Lymphocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention

Cardiology ◽  
2014 ◽  
Vol 127 (3) ◽  
pp. 169-175 ◽  
Author(s):  
Qiang Su ◽  
Lang Li ◽  
Yang Liu ◽  
You Zhou ◽  
Jiangyou Wang ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
T Lymphocytes ◽  
Unstable Angina ◽  
Coronary Intervention ◽  
Pdcd4 Expression ◽  
Percutaneous Coronary ◽  
Atorvastatin Therapy

The Clinical Effects of Nicorandil during Percutaneous Coronary Intervention in Patients with Unstable Angina

2005 ◽  
Vol 35 (4) ◽  
pp. 322 ◽  
Author(s):  
Ju Han Kim ◽  
Myung Ho Jeong ◽  
Sang Yup Lim ◽  
Sang Hyun Lee ◽  
Yun Sang Lee ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Unstable Angina ◽  
Coronary Intervention ◽  
Clinical Effects ◽  
Percutaneous Coronary

scholarly journals Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Shuai Shao ◽  
Zhaozhao Shi ◽  
Gary Tse ◽  
Xinghua Wang ◽  
Yanping Ni ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Endothelial Dysfunction ◽  
Unstable Angina ◽  
Myocardial Injury ◽  
Troponin I ◽  
Perioperative Period ◽  
Coronary Intervention ◽  
Control Group ◽  
Fatty Acid Binding ◽  
Percutaneous Coronary

Objectives. Trimetazidine is an anti-ischemic medication licensed for the treatment of angina pectoris. However, the molecular mechanisms underlying its action remain incompletely elucidated. In this study, therefore, we examined the potential beneficial effects of trimetazidine on myocardial injury and endothelial dysfunction in patients with unstable angina in the perioperative period of percutaneous coronary intervention (PCI). Methods. A total of 97 patients with unstable angina were randomly divided into trimetazidine (n = 48) and control (n = 49) groups. All subjects received standard medical therapy. The trimetazidine group additionally received 20 mg trimetazidine three times daily 24 hours before and after PCI. Serum levels of creatine kinase-muscle/brain (CK-MB), cardiac troponin I (cTnI), heart-type fatty acid-binding protein (h-FABP), von Willebrand factor (vWF), and nitric oxide (NO) were measured before and the morning following PCI. Results. In the control group, levels of CK-MB, cTnI, and vWF were significantly elevated (P<0.05) and NO level was decreased after PCI (P<0.05). By contrast, no significant changes in the levels of these proteins were observed in the trimetazidine group after PCI (P>0.05). Moreover, h-FABP levels were not significantly altered after PCI whether in the control or in the trimetazidine group (P>0.05). Finally, a time-dependent increase in the levels of h-FABP from 0 to 6 hours after PCI, followed by a progressive decline, was observed (P<0.05). Conclusions. PCI induces endothelial dysfunction and myocardial damage in patients with unstable angina. Trimetazidine therapy in the perioperative period can reduce this damage.

Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention

2005 ◽  
Vol 39 (4) ◽  
pp. 610-616 ◽  
Author(s):  
Thomas E Delea ◽  
Terry A Jacobson ◽  
Patrick WJC Serruys ◽  
John S Edelsberg ◽  
Gerry Oster
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Cost Effectiveness ◽  
Unstable Angina ◽  
Coronary Intervention ◽  
Model Parameters ◽  
Silent Ischemia ◽  
Lifestyle Counseling ◽  
Life Years ◽  
Percutaneous Coronary ◽  
The Cost

BACKGROUND: In the LIPS (Lescol Intervention Prevention Study), fluvastatin 80 mg/day reduced the risk of major adverse cardiac events (MACE) by 22% versus placebo (p = 0.01) following successful first percutaneous coronary intervention (PCI) in patients with stable or unstable angina or silent ischemia. The cost-effectiveness of such therapy is unknown. OBJECTIVE: To evaluate the cost-effectiveness of fluvastatin following successful first PCI from a US healthcare system perspective. METHODS: We used a Markov model to estimate expected outcomes and costs of 2 alternative treatment strategies following successful first PCI in patients with stable or unstable angina or silent ischemia: (1) diet/lifestyle counseling plus immediate fluvastatin 80 mg/day; and (2) diet/lifestyle counseling only, with initiation of fluvastatin 80 mg/day following occurrence of future nonfatal MACE. The model was estimated with data from LIPS and other published sources. Cost-effectiveness was calculated as the ratio of the difference in expected medical-care costs to the expected difference in life-years (LYs) and quality-adjusted life-years (QALYs) alternatively. RESULTS: Treatment with fluvastatin following successful first PCI was found to increase life expectancy by 0.78 years (QALYs 0.68). Cost-effectiveness of fluvastatin following successful first PCI is $13 505 per LY ($15 454 per QALY) saved. Ratios are lower for patients with diabetes ($9396 per LY; $10 718 per QALY) and those with multivessel disease ($9662 per LY; $11 076 per QALY). Findings were robust with respect to changes in key model parameters and assumptions. CONCLUSIONS: Fluvastatin therapy following PCI is cost-effective compared with other generally accepted medical interventions.

Sign in / Sign up

Export Citation Format

Share Document